Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

•Monoclonal antibodies against Aβ induced statistical improvements of small effect size for clinical outcomes in AD.•Monoclonal antibodies against Aβ induced statistical improvements of large effect size for biomarker outcomes and ARIA in AD.•Antibody effects on reducing amyloid PET deposition were correlated with their effects on improving cognition.•Among individual drugs, Aducanumab produced the most consistent effects, followed by Solanezumab.